Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501265 · ClinicalTrials.gov registry record · Phase 2
Adaptive Pharmacotherapy for Smoking Cessation
A Phase 2 study of Nicotine Dependence, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 1
- Study location
NCT02501265 is a Phase 2 study of Nicotine Dependence that has completed, run by Duke University. The registered enrollment target is 188 participants, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02501265, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigators hypothesize that participants allocated to adaptive therapy will show significantly higher biochemically confirmed 30-day continuous abstinence at 12 weeks post-Target Quit Day (TQD).
Conditions Studied
Interventions
- BEHAVIORAL Varenicline Standard Protocol
- BEHAVIORAL Nicotine Patch Standard Protocol
- DRUG Varenicline Adaptive Protocol
- DRUG Nicotine Adaptive Protocol
Study Locations (1)
North Carolina
- Duke Center for Smoking Cessation - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02501265
The ClinicalTrials.gov registry entry for NCT02501265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 4 interventions - of which Varenicline Standard Protocol is the first listed.
NCT02501265 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02501265 about?
NCT02501265 is a clinical study titled "Adaptive Pharmacotherapy for Smoking Cessation". The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigato...
What is the current status of trial NCT02501265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2017-06-06. Estimated completion is 2021-05-12.
What conditions does trial NCT02501265 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT02501265?
The interventions under investigation include: Varenicline Standard Protocol (BEHAVIORAL), Nicotine Patch Standard Protocol (BEHAVIORAL), Varenicline Adaptive Protocol (DRUG), Nicotine Adaptive Protocol (DRUG).
Who is sponsoring clinical trial NCT02501265?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02501265 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.